Market closed

Vaxart/$VXRT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Ticker

$VXRT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

109

Website

vaxart.com

Vaxart Metrics

BasicAdvanced

$164M

-

-$0.40

0.70 -

Price and volume

Market cap

$164M

Beta

0.7

52-week high

$1.54

52-week low

$0.52

Average daily volume

2.1M

Financial strength

Current ratio

0.827

Quick ratio

0.776

Long term debt to equity

25.492

Total debt to equity

33.716

Interest coverage (TTM)

-24.56%

Management effectiveness

Return on assets (TTM)

-32.91%

Return on equity (TTM)

-103.37%

Valuation

Price to revenue (TTM)

7.765

Price to book

2.39

Price to tangible book (TTM)

2.72

Price to free cash flow (TTM)

-2.535

Growth

Revenue change (TTM)

303.27%

Earnings per share change (TTM)

-36.02%

3-year revenue growth (CAGR)

142.59%

3-year earnings per share growth (CAGR)

-9.54%

What the Analysts think about Vaxart

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Vaxart stock.

Vaxart Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Vaxart Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Vaxart News

AllArticlesVideos

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

GlobeNewsWire·1 day ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewsWire·1 month ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VXRT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Vaxart stock?

Vaxart (VXRT) has a market cap of $164M as of January 15, 2025.

What is the P/E ratio for Vaxart stock?

The price to earnings (P/E) ratio for Vaxart (VXRT) stock is 0 as of January 15, 2025.

Does Vaxart stock pay dividends?

No, Vaxart (VXRT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Vaxart dividend payment date?

Vaxart (VXRT) stock does not pay dividends to its shareholders.

What is the beta indicator for Vaxart?

Vaxart (VXRT) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.